A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.
Inclusion Criteria:
Exclusion Criteria:
Buenos Aires, C1015, Argentina
Santa Fe, S2000PBJ, Argentina
Plovdiv, 4004, Bulgaria
Bogotá, 110221, Colombia
Elblag, 82-300, Poland
Warsaw, 02-637, Poland